TYRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Tyra Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$19.34+0.82 (+4.43%)
Close on Oct 19, 2026
- Market cap
- $1.28B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
69M of 60M shares
Institutional holders
170
33 new, 25 sold out
Net institutional buying
7M
In Q2 2026
Insider trades, 12 months
1 buys · 14 sales
Net sold $10.57M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC | 7,747,648 | 14.40% | 13G (passive) | Mar 31, 2026 |
| Lampert Mark N | 4,215,886 | 6.10% | 13G (passive) | Sep 14, 2026 |
| Janus Henderson Group PLC | 3,890,589 | 7.20% | 13G (passive) amendment | Mar 31, 2026 |
| Kim, David T. | 3,580,818 | 6.60% | 13G (passive) amendment | Mar 31, 2026 |
| Nextech VI GP S.a. r.l. | 3,553,585 | 6.00% | 13G (passive) amendment | Jun 30, 2026 |
| Paradigm BioCapital Advisors LP | 3,473,453 | 5.80% | 13G (passive) | Sep 10, 2026 |
| Linn, Michael G. | 2,984,818 | 5.60% | 13G (passive) | Feb 12, 2026 |
| BlackRock, Inc. | 2,976,228 | 5.00% | 13G (passive) | Jun 30, 2026 |
| Canaan XI L.P. | 2,930,444 | 5.50% | 13G (passive) amendment | Dec 31, 2025 |
| TCG Crossover GP I, LLC | 2,898,103 | 5.70% | 13G (passive) | Feb 27, 2025 |
| Commodore Capital LP | 2,750,000 | 5.20% | 13G (passive) | May 7, 2025 |
| Aaron I. Davis | 2,548,905 | 5.00% | 13D (active) amendment | Dec 4, 2024 |
| Peter Kolchinsky | 14,130,492 | 19.90% | 13D (active) amendment | Sep 15, 2026 |
| RA Capital Management, L.P. | 12,266,575 | 21.20% | 13D (active) amendment | Mar 4, 2026 |
| Rajeev Shah | 11,899,788 | 22.40% | 13D (active) amendment | Jun 4, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TYRA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 12,198,625 | 20.44% | $389.62M | – | 3.39% |
| FMR LLC | 8,920,513 | 14.95% | $284.92M | +1,172,865 | 0.01% |
| Jupiter Topco LLC | 4,352,448 | 7.29% | $139.16M | New | 0.06% |
| Alta Partners Management Company, L.P. | 3,823,425 | 6.41% | $122.12M | – | 95.92% |
| Nextech Invest, Ltd. | 3,553,585 | 5.95% | $113.50M | −502,276 | 5.39% |
| TCG Crossover Management, LLC | 3,248,980 | 5.44% | $103.77M | – | 2.49% |
| BlackRock, Inc. | 3,031,972 | 5.08% | $96.84M | +814,043 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 2,782,567 | 4.66% | $88.88K | +1,796,506 | 0.01% |
| State Street Corp | 2,140,368 | 3.59% | $68.36M | +924,290 | 0.00% |
| Commodore Capital LP | 1,875,000 | 3.14% | $59.89M | −600,000 | 3.57% |
| Paradigm Biocapital Advisors LP | 1,828,607 | 3.06% | $58.41M | −226,384 | 1.09% |
| Vanguard Capital Management LLC | 1,508,447 | 2.53% | $48.18M | +382,477 | 0.00% |
| Bvf Inc/Il | 1,476,196 | 2.47% | $47.15M | −500,000 | 1.21% |
| 5AM Venture Management, LLC | 1,029,298 | 1.72% | $32.88M | – | 11.42% |
| Deerfield Management Company, L.P. (Series C) | 1,017,000 | 1.70% | $32.48M | +468,000 | 0.34% |
| Hood River Capital Management LLC | 1,016,775 | 1.70% | $32.48M | New | 0.24% |
| Geode Capital Management, LLC | 970,734 | 1.63% | $31.01M | +312,252 | 0.00% |
| Caligan Partners LP | 806,986 | 1.35% | $25.78M | −469,982 | 1.21% |
| Canaan Partners XI LLC | 750,000 | 1.26% | $23.96M | – | 18.82% |
| Siren, L.L.C. | 725,000 | 1.21% | $23.16M | New | 0.47% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 170 | 69M | 100.0% | 33 / 73 | 44 / 25 | 17M | 10M |
| Q1 2026 | 164 | 66M | 100.0% | 46 / 60 | 35 / 14 | 22M | 11M |
| Q4 2025 | 133 | 57M | 95.2% | 29 / 43 | 38 / 10 | 6M | 4M |
| Q3 2025 | 116 | 56M | 93.4% | 9 / 41 | 37 / 14 | 2M | 3M |
| Q2 2025 | 121 | 57M | 94.9% | 18 / 62 | 20 / 14 | 7M | 4M |
| Q1 2025 | 117 | 54M | 89.8% | 22 / 42 | 31 / 16 | 13M | 4M |
| Q4 2024 | 113 | 49M | 81.5% | 36 / 34 | 25 / 18 | 12M | 11M |
| Q3 2024 | 95 | 47M | 79.5% | 25 / 29 | 20 / 8 | 4M | 2M |
| Q2 2024 | 79 | 47M | 79.1% | 18 / 30 | 17 / 16 | 3M | 3M |
| Q1 2024 | 77 | 47M | 79.3% | 22 / 26 | 15 / 7 | 12M | 1M |
| Q4 2023 | 62 | 36M | 60.7% | 9 / 21 | 12 / 6 | 1M | 2M |
| Q3 2023 | 59 | 36M | 61.1% | 4 / 16 | 16 / 4 | 1M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of TYRA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity OTC Portfolio | 3,295,446 | 5.52% | $105.06M | 0.24% | Jul 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,392,376 | 2.33% | $44.47M | 0.41% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,135,472 | 1.90% | $36.27M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 944,201 | 1.58% | $30.16M | 0.04% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 793,140 | 1.33% | $25.33M | 0.17% | Jun 30, 2026 |
| Fidelity Advisor Equity Growth Fund | 678,600 | 1.14% | $22.67M | 0.17% | May 31, 2026 |
| VIP Growth Portfolio | 630,800 | 1.06% | $20.15M | 0.16% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 558,500 | 0.94% | $17.84M | 0.18% | Jun 30, 2026 |
| Hood River Small-Cap Growth Fund | 492,217 | 0.82% | $15.72M | 0.24% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 402,231 | 0.67% | $12.82M | 0.04% | Jul 31, 2026 |
| Fidelity Stock Selector Small Cap Fund | 389,800 | 0.65% | $12.43M | 0.17% | Jul 31, 2026 |
| Fidelity Small Cap Growth Fund | 374,540 | 0.63% | $11.94M | 0.14% | Jul 31, 2026 |
| Janus Henderson Triton Fund | 357,107 | 0.60% | $11.41M | 0.19% | Jun 30, 2026 |
| Fidelity Advisor Biotechnology Fund | 354,200 | 0.59% | $11.29M | 0.51% | Jul 31, 2026 |
| Fidelity Growth Discovery Fund | 341,700 | 0.57% | $10.91M | 0.16% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Todd Harris | President and CEO, Director | 1,438,495 | 2.41% | Sep 17, 2026 |
| Yuliya Rueb | Vice President, Finance (PAO) | 11,258 | 0.02% | Sep 17, 2026 |
| Alan Fuhrman | Chief Financial Officer | 37,115 | 0.06% | Sep 17, 2026 |
| Bhavesh Ashar | Chief Operating Officer | 15,013 | 0.03% | May 7, 2026 |
| Douglas J. Warner | Chief Medical Officer | 25,000 | 0.04% | May 7, 2026 |
| Daniel Bensen | Chief Discovery Officer | 146,981 | 0.25% | Feb 13, 2026 |
| Capital Healthcare Fund LP RA | Director, 10% owner | 10,096,004 | 16.92% | Sep 17, 2026 |
| Rajeev M. Shah | Director, 10% owner | 8,477,275 | 14.21% | Sep 17, 2026 |
| Peter Kolchinsky | Director, 10% owner | 9,909,154 | 16.60% | Sep 17, 2026 |
| RA Capital Nexus Fund, L.P. | Director | 4,047,120 | 6.78% | Sep 17, 2026 |
| Ra Capital Management, L.P. | Director, 10% owner | 10,259,291 | 17.19% | Sep 17, 2026 |
| Rehan Verjee | Director | 972 | 0.00% | Sep 11, 2026 |
| Susan Moran | Director | 0 | – | Jun 1, 2026 |
| Adele M. Gulfo | Director | 4,000 | 0.01% | Jun 1, 2026 |
| Jake Simson | Director | – | – | Jun 1, 2026 |
| Stephen Michael Rothenberg | Director | 0 | – | Jun 1, 2026 |
| Robert J. More | Director | 3,823,425 | 6.41% | Jun 1, 2026 |
| Habib J. Dable | Director | 0 | – | Apr 20, 2026 |
| Gilla Kaplan | Director | 28,231 | 0.05% | Mar 27, 2026 |
| Nina S. Kjellson | Director | 4,144,590 | 6.95% | Feb 7, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Yuliya Rueb Vice President, Finance (PAO) | Sep 15, 2026 | Award | +2,925 | $9.13 | $26.71K | 11,258 |
| Todd Harris President and CEO, Director | Sep 15, 2026 | Award | +864 | $9.13 | $7.89K | 1,438,495 |
| Alan Fuhrman Chief Financial Officer | Sep 15, 2026 | Award | +951 | $9.13 | $8.68K | 37,115 |
| Rehan Verjee Director | Sep 9, 2026 | Buy | +971.89 | $20.58 | $20.00K | 972 |
| Yuliya Rueb Vice President, Finance (PAO) | May 5, 2026 | Award | +8,333 | – | – | 43,354 |
| Todd Harris President and CEO, Director | May 5, 2026 | Award | +79,000 | – | – | 1,437,631 |
| Alan Fuhrman Chief Financial Officer | May 5, 2026 | Award | +20,000 | – | – | 36,164 |
| Douglas J. Warner Chief Medical Officer | May 5, 2026 | Award | +25,000 | – | – | 25,000 |
| Bhavesh Ashar Chief Operating Officer | May 5, 2026 | Award | +15,013 | – | – | 15,013 |
| Gilla Kaplan Director | Mar 26, 2026 | Returned to company | −53,172 | $37.75 | $2.01M | 28,231 |
| Gilla Kaplan Director | Mar 26, 2026 | Option exercise | −53,172 | $2.25 | $119.64K | 81,403 |
| Gilla Kaplan Director | Mar 25, 2026 | Option exercise | +14,295 | $2.25 | $32.16K | 42,526 |
| Gilla Kaplan Director | Mar 25, 2026 | Sale | −14,295 | $36.97 | $528.49K | 28,231 |
| Alan Fuhrman Chief Financial Officer | Mar 13, 2026 | Award | +1,376 | $9.13 | $12.56K | 16,164 |
| Todd Harris President and CEO, Director | Mar 13, 2026 | Award | +1,463 | $9.13 | $13.36K | 1,358,631 |
| Daniel Bensen Chief Discovery Officer | Feb 12, 2026 | Sale(10b5-1 plan) | −5,872 | $33.37 | $195.95K | 146,981 |
| Daniel Bensen Chief Discovery Officer | Feb 12, 2026 | Sale(10b5-1 plan) | −2,128 | $31.50 | $67.03K | 152,853 |
| Daniel Bensen Chief Discovery Officer | Jan 12, 2026 | Sale(10b5-1 plan) | −1,017 | $29.08 | $29.57K | 154,981 |
| Daniel Bensen Chief Discovery Officer | Jan 12, 2026 | Sale(10b5-1 plan) | −6,983 | $28.44 | $198.60K | 155,998 |
| Robert J. More Director | Dec 19, 2025 | Sale(10b5-1 plan) | −10,000 | $25.00 | $250.00K | 3,823,425 |
| Daniel Bensen Chief Discovery Officer | Dec 12, 2025 | Sale(10b5-1 plan) | −8,000 | $22.64 | $181.12K | 162,981 |
| Robert J. More Director | Nov 21, 2025 | Sale(10b5-1 plan) | −246,871 | $20.25 | $5.00M | 3,833,425 |
| Daniel Bensen Chief Operating Officer | Nov 19, 2025 | Sale(10b5-1 plan) | −49,956 | $16.32 | $815.28K | 170,981 |
| Daniel Bensen Chief Operating Officer | Nov 18, 2025 | Sale(10b5-1 plan) | −75,633 | $16.07 | $1.22M | 220,937 |
| Daniel Bensen Chief Operating Officer | Nov 17, 2025 | Sale(10b5-1 plan) | −18,572 | $16.11 | $299.19K | 298,070 |
| Daniel Bensen Chief Operating Officer | Nov 17, 2025 | Sale(10b5-1 plan) | −1,500 | $17.07 | $25.61K | 296,570 |
| Daniel Bensen Chief Operating Officer | Nov 14, 2025 | Sale(10b5-1 plan) | −110,228 | $16.02 | $1.77M | 316,642 |
| Daniel Bensen Chief Operating Officer | Nov 13, 2025 | Sale(10b5-1 plan) | −1,111 | $16.00 | $17.78K | 426,870 |
| Alan Fuhrman Chief Financial Officer | Sep 15, 2025 | Award | +701 | $9.13 | $6.40K | 14,788 |
| Gilla Kaplan Director | Jun 18, 2025 | Sale | −9,568 | $9.78 | $93.58K | 28,231 |
| Gilla Kaplan Director | Jun 17, 2025 | Sale | −10 | $10.35 | $104 | 37,799 |
| Gilla Kaplan Director | Jun 16, 2025 | Sale | −6,814 | $10.38 | $70.73K | 37,809 |
| Ra Capital Management, L.P. Director, 10% owner | Jun 16, 2025 | Buy | +11,813 | $10.13 | $119.67K | 10,259,291 |
| Gilla Kaplan Director | Jun 13, 2025 | Sale | −15,000 | $10.31 | $154.65K | 44,623 |
| Ra Capital Management, L.P. Director, 10% owner | Jun 13, 2025 | Buy | +120,167 | $10.20 | $1.23M | 10,247,478 |
| Gilla Kaplan Director | Jun 12, 2025 | Sale | −30,000 | $10.31 | $309.30K | 59,623 |
| Ra Capital Management, L.P. Director, 10% owner | Jun 12, 2025 | Buy | +31,307 | $10.20 | $319.33K | 10,127,311 |
| Capital Healthcare Fund LP RA Director, 10% owner | Jun 9, 2025 | Buy | +186,850 | $10.19 | $1.90M | 10,096,004 |
| Peter Kolchinsky Director, 10% owner | Jun 5, 2025 | Buy | +213,334 | $10.04 | $2.14M | 9,909,154 |
| Peter Kolchinsky Director, 10% owner | Jun 4, 2025 | Buy | +997,864 | $9.63 | $9.61M | 9,695,820 |
| Todd Harris President and CEO, Director | Mar 14, 2025 | Award | +1,241 | $9.78 | $12.14K | 1,357,168 |
| Alan Fuhrman Chief Financial Officer | Mar 14, 2025 | Award | +1,238 | $9.78 | $12.11K | 14,087 |
| Nina S. Kjellson Director | Feb 5, 2025 | Sale | −3,511 | $13.76 | $48.31K | 443,885 |
| Nina S. Kjellson Director | Feb 5, 2025 | Sale | −1,890 | $13.76 | $26.01K | 3,700,705 |
| Nina S. Kjellson Director | Jan 23, 2025 | Sale | −4,825 | $16.26 | $78.45K | 3,702,595 |
| Nina S. Kjellson Director | Jan 21, 2025 | Sale | −3,993 | $16.36 | $65.33K | 3,707,420 |
| Nina S. Kjellson Director | Jan 17, 2025 | Sale | −12,808 | $16.40 | $210.05K | 3,711,413 |
| Nina S. Kjellson Director | Jan 17, 2025 | Sale | −461 | $16.40 | $7.56K | 447,396 |
| Nina S. Kjellson Director | Jan 16, 2025 | Sale | −835 | $16.29 | $13.60K | 447,857 |
| Nina S. Kjellson Director | Jan 16, 2025 | Sale | −6,944 | $16.29 | $113.12K | 3,724,221 |
| Nina S. Kjellson Director | Nov 25, 2024 | Sale | −566 | $16.84 | $9.53K | 448,692 |
| Nina S. Kjellson Director | Nov 25, 2024 | Sale | −4,706 | $16.84 | $79.25K | 3,731,165 |
| Capital Healthcare Fund LP RA Director, 10% owner | Nov 8, 2024 | Buy | +1,220,681 | $16.25 | $19.84M | 8,697,956 |
| Nina S. Kjellson Director | Nov 7, 2024 | Sale | −19,720 | $17.32 | $341.55K | 3,735,871 |
| Nina S. Kjellson Director | Nov 7, 2024 | Sale | −2,371 | $17.32 | $41.07K | 449,258 |
| Nina S. Kjellson Director | Nov 6, 2024 | Sale | −5,635 | $17.18 | $96.81K | 451,629 |
| Nina S. Kjellson Director | Nov 6, 2024 | Sale | −46,856 | $17.18 | $804.99K | 3,755,591 |
| Nina S. Kjellson Director | Nov 5, 2024 | Sale | −1,126 | $16.77 | $18.88K | 457,264 |
| Nina S. Kjellson Director | Nov 5, 2024 | Sale | −9,367 | $16.77 | $157.08K | 3,802,447 |
| Nina S. Kjellson Director | Nov 4, 2024 | Sale | −116 | $17.01 | $1.97K | 458,390 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Vi Oncology Scsp Nextech Shareholder | Jun 26, 2026 | 308,379 | $9.54M | Jun 26, 2026 | Private Placement |
| Vi Oncology Scsp Nextech Shareholder | Jun 1, 2026 | 300,000 | $10.02M | Jun 1, 2026 | Private Placement |
| Bensen Daniel Officer | May 12, 2026 | 8,000 | $274.00K | May 12, 2026 | Founders shares |
| Bensen Daniel Officer | Apr 13, 2026 | 8,000 | $285.00K | Apr 13, 2026 | Founders shares |
| Kaplan Gilla Director | Mar 26, 2026 | 53,172 | $2.01M | Mar 26, 2026 | Stock Option Exercise |
| Kaplan Gilla Director | Mar 25, 2026 | 14,295 | $528.51K | Mar 25, 2026 | Stock Option Exercise |
| Bensen Daniel Officer | Mar 12, 2026 | 8,000 | $283.00K | Mar 12, 2026 | Founders shares |
| Bensen Daniel Officer | Feb 12, 2026 | 8,000 | $262.00K | Feb 12, 2026 | Founders shares |
| Bensen Daniel Officer | Jan 12, 2026 | 8,000 | $232.00K | Jan 12, 2026 | Founders shares |
| Bensen Daniel Officer | Dec 12, 2025 | 8,000 | $180.00K | Dec 12, 2025 | Founders shares |
| Alta Partners NextGen Fund II, L.P. Affiliate | Nov 21, 2025 | 256,871 | $5.39M | Nov 21, 2025 | Private Placement |
| Bensen Daniel Officer | Nov 18, 2025 | 124,589 | $2.00M | Nov 18, 2025 | Founders shares |
| Bensen Daniel Officer | Nov 17, 2025 | 20,072 | $320.00K | Nov 17, 2025 | Founders shares |
| Bensen Daniel Officer | Nov 14, 2025 | 86,339 | $1.38M | Nov 14, 2025 | Founders shares |
| Bensen Daniel Officer | Nov 13, 2025 | 25,000 | $400.00K | Nov 13, 2025 | Founders shares |